Vicapsys Life Sciences, Inc.
Vicapsys focuses on leveraging natural pathways in a localized manner to achieve therapeutic benefits without systemic negative consequences. Their core technology is a pleiotropic cytokine, CXCL12, formulated for various indications. The company is currently focused on curing Type 1 diabetes through long-term survival of transplanted islet cells. They also address the consequences of diabetes and localized fibrosis.
Registre Officiel
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
vTv Therapeutics Inc.
vTv Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of diabetes patients. They focus on developing oral, small molecule drug candidates. Their lead candidate is cadisegliatin, a potential adjunctive therapy to insulin for type 1 diabetes. They are also exploring indications for type 2 diabetes and other chronic conditions.
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biotech company working to harness the power of the immune system to improve lives and eradicate cancer. The company is developing novel immunotherapies using foreign patterns to trigger the innate immune system, which teaches the immune system to recognize and kill cancer. Bolt was founded in 2015.
IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. They are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors.